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Background: Our previous report showed an association between age
and outcome in gefitinib-treated female patients with non-small cell
lung cancer (NSCLC). Only limited numbers of molecular studies have
been performed with respect to the presence of epidermal growth factor
receptor (EGFR) mutations according to age. This retrospective study
was performed to evaluate a possible association between age at the
time diagnosis and the presence of EGFR mutations in female patients
with NSCLC.
Methods: Tumor specimens were collected retrospectively from par-
affin blocks of 98 female patients with primary NSCLCwho underwent
surgical resection between January 1992 and December 2002 at the
Korea Cancer Center Hospital. To detect EGFR mutations, a Scorpion
Amplified Refractory Mutation System was used.
Results:Most of the study population comprised never smokers (84%)
and patients with adenocarcinoma (82%). The age at the time of
diagnosis ranged from 34 to 74 years (median, 57 years). When the
median age was used as a cutoff value, older patients were more likely
to have EGFR mutations than younger patients (70 versus 39%; p 
0.004). After controlling for the effects of histology, smoking history,
and stage, age remained a significant predictor for EGFR mutations
(odds ratio, 4.03; 95% confidence interval, 1.61–10.09; p  0.003).
Conclusions: Our data suggest that age at the time of diagnosis in
female patients with NSCLC may be associated with the frequency
of EGFR mutations, a strong indicator for favorable outcomes.
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Lung cancer has been the leading cause of cancer-relateddeaths in both men and women for the past 30 years.1
Historically, lung cancer has been more prevalent in men than in
women.1,2 Because the incidence of lung cancer in women has
risen, there is increased concern with female lung cancer.1,3–7
Compared with male counterparts, female patients with
non-small cell lung cancer (NSCLC) have distinct clinical fea-
tures.1,8–12 The proportion of never smokers and adenocarcino-
mas8,12 is higher in females than males. In addition, females
have favorable outcomes after treatment with tyrosine kinase
inhibitors (TKIs) such as gefitinib or erlotinib.13–15
Recent studies have shown that females are more likely to
have epidermal growth factor receptor (EGFR) mutations, the
majority of which consist of an in-frame deletion in exon 19 and
a point mutation involving the replacement of leucine with
arginine at codon 858 in exon 21.16–18 Because of the predictive
role of EGFR mutations with respect to TKIs, mutational tests
may be useful in selecting patients who will benefit with TKI
therapy.9,10,18–20 However, molecular findings are often unavail-
able due to insufficient tissue in clinical practice.
Previously, we evaluated the clinical significance of age
at the time of diagnosis in gefitinib-treated females.6 Consider-
ing the role of EGFR mutations,9,10,18–20 it is possible that the
age at the time of diagnosis may be associated with the presence
of EGFR mutations in females. However, there are few studies
that have addressed this association. Thus, in this retrospective
study, we evaluated the possible association between age and the
presence of EGFR mutations in females.
PATIENTS AND METHODS
Patients and Tissues
Archived tissue blocks were retrieved from the data of
females with primary NSCLC who underwent surgical resection
between January 1992 and December 2002 at the Korea Cancer
Center Hospital. The patients eligible for the study were col-
lected from the NSCLC pathology database of our institution.
We excluded four patients with pleural seeding and bone me-
tastasis detected at the time of exploration. Patients with a
history of malignancy within 5 years were excluded. Ninety-
eight patients were analyzed in this study. The age at the time of
initial diagnosis and smoking status were obtained from the
hospital medical records. The postoperative stage was adopted
by the international system for lung cancer in 1997.21 This study
was approved by the Institutional Review Board of Korea
Cancer Center Hospital.
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The Scorpion Amplified Refractory Mutation
System for the Detection of EGFR Mutations
DNAwas extracted from paraffin-embedded tissues using
previously described methods.22 To detect EGFRmutations, the
Scorpion Amplified Refractory Mutation System was used.23,24
The system enables the detection of G719X, L858R, and L861Q
substitutions and deletions in exon 19 in the EGFR gene.
Amplification was done in 25 L volumes using 5 L of
template DNA, 16 L of reaction buffer mix, 4 L of Taq
polymerase, and water. Real-time polymerase chain reaction
was carried out using the ABI 7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA) under the following
conditions: initial denaturation at 95°C for 10 minutes and 40
cycles of 95°C for 30 seconds and 61°C for 60 seconds with
fluorescence reading at the end of each cycle. Data were ana-
lyzed using 7500 System SDS software (version 1.3.1; Applied
Biosystems). The cycle threshold (Ct) was defined as the cycle
at the threshold fluorescence under which the signal was con-
sidered to be background noise. Sample Ct values were cal-
culated as the difference between the mutation Ct and control Ct.
If the Ct was smaller than the difference between the back-
ground and control Ct, the sample was considered positive.
Statistical Analysis
The relationships between EGFR mutations and other
clinicopathological parameters, such as histology (adenocarci-
noma versus nonadenocarcinoma), stage, age, and smoking
status, were compared using the 2 test, Fisher’s exact proba-
bility test, or linear-by-linear association, where appropriate.
Logistic regression models were used for analysis to further
clarify the observed differences and to identify clinical factors
that might independently predict an EGFR mutation. All statis-
tical analyses were carried out using SPSS software (version
14.0; SPSS, Inc., Chicago, IL), and p  0.05 was defined as
being statistically significant. All statistical tests were two sided.
RESULTS
Patient Characteristics
Table 1 shows the characteristics of the 98 female patients
diagnosed with NSCLC who had undergone curative resection
and subjected analysis. The median age was 57 years (range,
34–74 years). The major histologic type was adenocarcinoma
(81 cases), including 6 cases of bronchioloalveolar carcinoma,
followed by squamous (12 cases), adenosquamous (4 cases), and
adenoid cystic (1 case) carcinoma. Most individuals were never
smokers (84%). The postoperative stage was as follows: 38
patients, stage I; 24 patients, stage II; and 36 patients, stage III.
Detection of EGFR Mutations
We analyzed the EGFR mutation status of 98 patients
using the EGFR Scorpion kit.24 EGFRmutations associated with
a good clinical response to gefitinib or erlotinib9,16,18,25,26 were
found in 53 of 98 cases (54%). These EGFRmutations included
in-frame deletions within exon 19 (n 40), L858R substitutions
in exon 21 (n 12), and a G719X substitution in exon 18 (n
1; Table 1). The frequency of EGFR mutations was not signif-
icantly different between patients with adenocarcinomas and
nonadenocarcinomas (56 versus 47%; p 0.598) and never and
ever smokers (56 versus 57%; p 1.000). In addition, incidence
of EGFR mutation according to stage did not reach a statistical
difference (p  0.067; Table 2).
TABLE 1. Patient Characteristics (n  98)
Characteristics No. of Cases (%)
Age (yr)
Median 57 (range, 34–74)
57 49 (50)
57 49 (50)
Histology
Adenocarcinomaa 81 (83)
Nonadenocarcinoma 17 (17)
Squamous cell carcinoma 12
Adenosquamous carcinoma 4
Adenoid cystic carcinoma 1
Stage
I 38 (39)
II 24 (24)
III 36 (37)
Smoking history
Ever smoker 16 (16)
Never smoker 82 (84)
EGFR mutations 53 (54)
Exon 18 G719X 1 (1)
Exon 19 deletion 40 (41)
Exon 21 L858R 12 (12)
a Including six bronchiloloalveolar carcinomas.
EGFR, epidermal growth factor receptor.
TABLE 2. Association Between EGFR Mutations and
Clinical Features in Female Patients Diagnosed with NSCLC
Based on Univariate Analysis
Characteristics
No. of EGFR
Mutations (%) p
Total 53 (54)
Age (yr)
57 19 (39) 0.004
57 34 (69)
Histology
Adenocarcinomaa 45 (57) 0.598
Nonadenocarcinoma 8 (47)
Squamous cell carcinoma 6
Adenosquamous carcinoma 2
Adenoid cystic carcinoma 0
Stage
I 17 (45) 0.067
II 11 (46)
III 25 (69)
Smoking history
Ever smoker 9 (56) 1.000
Never smoker 44 (57)
a Including six bronchiloloalveolar carcinomas.
EGFR, epidermal growth factor receptor.
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Association of EGFR Mutations with Age at the
Time of Diagnosis
When the median age (57 years) was used as a cutoff
value, older patients were more likely to have EGFR mutations
than younger patients (70 versus 39%; p 0.004; Table 2). We
further analyzed the association between EGFR mutations and
the age at the time of diagnosis. Patients were grouped in 5-year
age increments, starting from younger than 45 years to older
than 65 years. Each group consists of more than 12 patients. As
shown in Figure 1, only 30% of patients younger than 45 years
harbored EGFR mutations, whereas 70% of patients older than
65 years did. Linear-by-linear analysis revealed that EGFR
mutations were strongly associated with the age at the time of
diagnosis (p  0.004). Importantly, after adjusting for age,
histology, smoking status, and stage, multivariate analysis dis-
closed independent significant differences in the presence of
EGFR mutations according to older age at the time of NSCLC
diagnosis (odds ratio, 4.03; 95% confidence interval, 1.61–
10.09; p  0.003; Table 3).
DISCUSSION
In this study, we evaluated the possibility of an association
between age at the time of diagnosis and the presence of EGFR
mutations in female patients with NSCLC. EGFR mutations
existed in 54% of the patients, which is consistent with results of
previous studies.16,17,19 EGFR mutations were found more fre-
quently as the age at the time of diagnosis increased. Impor-
tantly, after controlling effects that are suggested to be associ-
ated with EGFR mutations (i.e., histology and smoking
history),16–18 age remained a significant factor.
This study is the first study to examine the association
between age and EGFR mutations in female patients with
NSCLC. In our data, the majority of female patients had history
of never smoking and adenocarcinoma histology, which are
associated with high prevalence of EGFR mutation, a strong
predictor for TKI responsiveness.9,10,18–20 Although the different
incidence of EGFR mutation in female, in addition to never
smokers and adenocarcinomas, has been observed in patients
with early stage,16,27,28 potential significance of age in female
patients was not fully evaluated. Previously, our retrospective
data on gefitinib-treated female patients showed that older age at
the time of diagnosis predicted prolonged progression-free sur-
vival (hazard ratio, 0.60; p 0.008) and overall survival (hazard
ratio, 0.60; p  0.014).6 These findings are partly in agreement
with the results of another study in Asia, which showed a
different survival benefit with gefitinib according to age
(younger than 65 years: hazard ratio, 0.81; 65 years or older:
hazard ratio, 0.58; p  0.026 for the interaction of treatment
with age).19 It should be noted that female patients were pre-
dominantly included in that study (79.5% of the total popula-
tion). Interestingly, the molecular analysis suggests higher inci-
dence of EGFR mutation in older patients than in younger ones
(68 versus 57% respectively; calculated p  0.05). Theoreti-
cally, it is possible that the potential statistical strength of age in
female patients might be weakened if male patients had been
included. Further studies to evaluate the impact of age according
to gender are needed.
Recent studies have suggested an effect of female hor-
mones on EGFR mutations.5,25 Some investigators have shown
that the expression of estrogen receptors was associated with a
high prevalence of EGFR mutations.29,30 Although one case-
control study also suggested that longer endogenous estrogen
exposure may be a risk factor for EGFR-mutant NSCLC,5 there
are few data to explain the association of aging with EGFR
mutations in female patients. Therefore, further large-scale stud-
ies are required to clarify the underlying mechanisms for these
observations.
This retrospective study had several limitations. First, this
study was performed in patients with a different clinical setting
from distant metastasis. Invasive methods to obtain sufficient
tissues are frequently difficult in patients with advanced sta-
ges,31,32 which is the reason for selecting resected tumors in this
study. Considering the statistical value to suggest the different
incidence of EGFR mutations within early stages (Table 3), we
cannot exclude the possibility of selection bias in respect to
stage. However, the frequency of EGFR mutation in this study
is within the range reported previously.16,19 The predominance
of EGFR mutations in more advanced stage also seems to be
unclear in previous studies.16,17,28 Although another potential
association between stage and age should be considered,33,34
similar prevalence of advanced stage in old age has been
reported.35,36 Despite a plausible bias in the limited population of
early stage, we believe that the significance of age in respect to
the prevalence of EGFR mutation is worthy of further research.
Second, the data consisted of a small number of patients col-
lected from a single institution. Thus, the small sample size did
FIGURE 1. EGFR mutations were strongly associated with
the age at the time of diagnosis (p  0.004). *Number of
patients with EGFR mutations/number of total patients in
each group.
TABLE 3. The Presence of EGFR Mutations According to
Clinical Factors Based on Multivariate Analysis
Characteristics Odds Ratio 95% CI p
Age 57 yr 4.03 1.61–10.09 0.003
Adenocarcinoma 2.21 0.44–6.36 0.213
Ever smoker 1.67 0.44–6.36 0.450
Stage — — 0.080
II 0.79 0.54–5.23 0.375
III 5.02 1.16–9.31 0.029
EGFR, epidermal growth factor receptor; CI, confidence interval.
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not allow the detection of a significant correlation between the
prevalence of EGFR mutations and smoking status or histology
type. However, the predominance of never smokers and adeno-
carcinoma histology in female patients is in agreement with
other studies in Asia.4,8 Furthermore, some investigators have
reported that smoking history is not statistically associated with
clinical outcomes in female patients.3,6
Our study suggests that the age at the time of diagnosis
may be predictive of EGFR mutations in female patients with
NSCLC. In the clinical setting, when molecular tests are un-
available, age might be useful in considering the TKI treatment
for female lung cancer patients. Further large-scale studies with
patients of diverse ethnic backgrounds should be undertaken to
validate these findings.
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